Table 3.
Clinical characteristics and receptor prevalence.
| Characteristics and Presence of Receptors | Total (N=22) |
|---|---|
| FIGO Stage, n (%) | |
| I | 3 (13.6%) |
| III | 17 (77.3%) |
| IV | 2 (9.09%) |
| Grade, n (%) | |
| 2 | 2 (9.09%) |
| 3 | 10 (45.45%) |
| 4 | 7 (31.81%) |
| Not documented | 3 |
| Histology, n (%) | |
| Endometrioid | 3 (13.6%) |
| Mucinous | 1 (4.5%) |
| Serous | 18 (81.81%) |
| Debulking status, n (%) | |
| Optimal (1- 10cm) | 20 (90.90%) |
| Sub-optimal (>10cm) | 2 (9.09%) |
| mRNA | |
| ALK2 and ALK3 | 22 (100%) |
| ALK6 | 12 (54.5%) |
| MISR2 | 14 (63.6%) |
| Protein | |
| ALK2 and ALK3 | 21 (95%) |
| ALK6 | 11 (50%) |
| MISR2 | 14 (63.6%) |